Tags

Type your tag names separated by a space and hit enter

Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin.
Bone Marrow Transplant. 2000 Jul; 26(2):119-25.BM

Abstract

Between February 1998 and October 1999, 24 patients with advanced leukemia, lymphoma or solid tumors received G-CSF mobilized peripheral blood stem cells (PBSC) from HLA-matched sibling donors after dose-reduced conditioning therapy. Only patients with reduced performance status or major infectious complications, not eligible for standard transplant procedures, were included. The 5-day conditioning therapy consisted of 3.3 mg/kg intravenous busulphan x 2 days and 30 mg/m2 fludarabine x 5 days. GVHD prophylaxis was performed with either CsA alone (n = 5), CsA combined with short course methotrexate (n = 5) or mycophenolate mofetil (n = 14). The day 100 survival was 95.2% for the whole group. All patients engrafted after a median of 15 days (range, 11-19) and 12.5 days (range, 10-19) for neutrophils and platelets, respectively. The median time to a neutrophil count of <0.5 x 109/l was 7 days (range, 2 to 12). Acute GVHD >I was observed in six patients, whereas eight patients have signs of chronic GVHD. The prospective 12 month overall survival with a median follow-up of 7 months is 63%. Relapse of disease and toxicity associated with chronic GVHD were the main causes of death. The treatment-related mortality was 12.5%. Dose-reduced conditioning using intravenous busulphan and fludarabine allows stable engraftment without ATG in related transplants and leads to a reduction of transplant-related mortality.

Authors+Show Affiliations

Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus, Dresden, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10918420

Citation

Bornhäuser, M, et al. "Dose-reduced Conditioning for Allogeneic Blood Stem Cell Transplantation: Durable Engraftment Without Antithymocyte Globulin." Bone Marrow Transplantation, vol. 26, no. 2, 2000, pp. 119-25.
Bornhäuser M, Thiede C, Schuler U, et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplant. 2000;26(2):119-25.
Bornhäuser, M., Thiede, C., Schuler, U., Platzbecker, U., Freiberg-Richter, J., Helwig, A., Plettig, R., Röllig, C., Naumann, R., Kroschinsky, F., Neubauer, A., & Ehninger, G. (2000). Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone Marrow Transplantation, 26(2), 119-25.
Bornhäuser M, et al. Dose-reduced Conditioning for Allogeneic Blood Stem Cell Transplantation: Durable Engraftment Without Antithymocyte Globulin. Bone Marrow Transplant. 2000;26(2):119-25. PubMed PMID: 10918420.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. AU - Bornhäuser,M, AU - Thiede,C, AU - Schuler,U, AU - Platzbecker,U, AU - Freiberg-Richter,J, AU - Helwig,A, AU - Plettig,R, AU - Röllig,C, AU - Naumann,R, AU - Kroschinsky,F, AU - Neubauer,A, AU - Ehninger,G, PY - 2000/8/5/pubmed PY - 2001/2/28/medline PY - 2000/8/5/entrez SP - 119 EP - 25 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 26 IS - 2 N2 - Between February 1998 and October 1999, 24 patients with advanced leukemia, lymphoma or solid tumors received G-CSF mobilized peripheral blood stem cells (PBSC) from HLA-matched sibling donors after dose-reduced conditioning therapy. Only patients with reduced performance status or major infectious complications, not eligible for standard transplant procedures, were included. The 5-day conditioning therapy consisted of 3.3 mg/kg intravenous busulphan x 2 days and 30 mg/m2 fludarabine x 5 days. GVHD prophylaxis was performed with either CsA alone (n = 5), CsA combined with short course methotrexate (n = 5) or mycophenolate mofetil (n = 14). The day 100 survival was 95.2% for the whole group. All patients engrafted after a median of 15 days (range, 11-19) and 12.5 days (range, 10-19) for neutrophils and platelets, respectively. The median time to a neutrophil count of <0.5 x 109/l was 7 days (range, 2 to 12). Acute GVHD >I was observed in six patients, whereas eight patients have signs of chronic GVHD. The prospective 12 month overall survival with a median follow-up of 7 months is 63%. Relapse of disease and toxicity associated with chronic GVHD were the main causes of death. The treatment-related mortality was 12.5%. Dose-reduced conditioning using intravenous busulphan and fludarabine allows stable engraftment without ATG in related transplants and leads to a reduction of transplant-related mortality. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/10918420/Dose_reduced_conditioning_for_allogeneic_blood_stem_cell_transplantation:_durable_engraftment_without_antithymocyte_globulin_ L2 - https://doi.org/10.1038/sj.bmt.1702500 DB - PRIME DP - Unbound Medicine ER -